Login / Signup

P63 and P73 Activation in Cancers with p53 Mutation.

Bi-He CaiYun-Chien HsuFang-Yu YehYu-Rou LinRui-Yu LuSi-Jie YuJei-Fu ShawMing-Han WuYi-Zhen TsaiYing-Chen LinZhi-Yu BaiYu-Chen ShihYi-Chiang HsuRuo-Yu LiaoWei-Hsin KuoChao-Tien HsuChing-Feng LienChia-Chi Chen
Published in: Biomedicines (2022)
The members of the p53 family comprise p53, p63, and p73, and full-length isoforms of the p53 family have a tumor suppressor function. However, p53, but not p63 or p73, has a high mutation rate in cancers causing it to lose its tumor suppressor function. The top and second-most prevalent p53 mutations are missense and nonsense mutations, respectively. In this review, we discuss possible drug therapies for nonsense mutation and a missense mutation in p53. p63 and p73 activators may be able to replace mutant p53 and act as anti-cancer drugs. Herein, these p63 and p73 activators are summarized and how to improve these activator responses, particularly focusing on p53 gain-of-function mutants, is discussed.
Keyphrases
  • intellectual disability
  • emergency department
  • autism spectrum disorder
  • wild type
  • inflammatory response